Abstract P4-09-11: microRNA markers and risk of recurrence in women with ductal carcinoma in situ

Abstract

Abstract Background: Women with DCIS have increased risk for invasive breast cancer. Limited abilities to accurately identify aggressive DCIS have resulted in inappropriate treatment for many women with mammographically-detected DCIS. miRNAs play a critical role in tumorigenesis. It remains unknown if miRNAs are associated with recurrence and refine risk assessment for DCIS patients. Methods: The study included 16 DCIS cases that developed ipsilateral recurrence (cases) and 32 DCIS cases that did not develop any type of recurrence (controls). Cases and controls were treated with breast conserving surgery and matched on age, race, and year of diagnosis. Expression of 96 cancer-related miRNAs was quantified using RT-PCR. Results: Two miRNAs were differentially expressed between cases and controls (p<0.05). A combination of the two miRNA markers was significantly associated with recurrence risk (odd ratio=2.60 per 1-unit increase, 95% confidence interval=1.14-8.13), which was independent of family history of breast cancer, radiation and endocrine therapy. The miRNA-based score (c-statistic=0.73) performed better than individual miRNAs (c-statistic=0.64-0.69) in discriminating DCIS cases who did and did not develop recurrence. Conclusion: miRNA expression in DCIS was associated with recurrence risk, which warrants further investigations to identify new miRNA markers by including more DCIS cases and analyzing all breast cancer-related miRNAs. Citation Format: Liu Y, Baker C, Wang X, Colditz G. microRNA markers and risk of recurrence in women with ductal carcinoma in situ. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-09-11.